Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.
Stanford researchers developed a technology that efficiently identifies combinations of genetic interventions with lasting, effective therapeutic functions by constructing genetic perturbation libraries containing the desired combination of phenotypes extracted from each cell.
The potency of cancer immunotherapies for solid tumors are often diminished by inadequate metabolic reprogramming and resulting immune evasion in cancer.
Researchers in the Mackall lab at Stanford have developed an adoptive cell therapy modification that enhances anti-tumor activity by disrupting a specific group of genes.
Researchers at Stanford have developed a microparticle-based vaccine that in a single shot enables enhanced activation of CD8+ and/or CD4+ T cells to fight against infectious diseases and cancer.
Researchers at Stanford have developed chemically defined, polyvinyl alcohol (PVA)-based media for culturing hematopoietic stem cells and immune cells (e.g., T cells).
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an efficacious therapy for patients with life-threatening leukemias, but its use has been hindered by the limited availability of donors with matching HLA. Graft manipulation by removing ??
Researchers at Stanford have developed agents to enhance the therapeutic efficacy of a variety of anti-cancer therapeutics. Cell loss by apoptosis occurs in normal development and in tumor environments.
Researchers at Stanford have developed chimeric antigen receptors (CARs) that target glypican-2 (GPC2) and can be used to treat solid tumors. CAR-engineered T cells have shown great promise as cancer therapeutics.